Today, Vertex Pharmaceuticals Inc. released the initial Phase 3 clinical trial data for one of two next-generation, triple-combination modulators currently being tested.
Site Search
Showing 21 - 30 of 125 results
News
|
|
1 min read
News
|
|
3 min read
Phase 2 clinical trial results were announced today for a potential next-generation modulator to treat people with two copies of the most common cystic fibrosis mutation, F508del.
News
|
|
2 min read
A new drug intended to make it easier to clear mucus from the lungs of people with cystic fibrosis showed promising results in a Phase 2 clinical trial. The drug, called SPX-101, blocks the overactive sodium channels that line CF lung cells.
News
|
|
2 min read
Today Vertex Pharmaceuticals Inc. announced the two next-generation CFTR modulator candidates that will progress into Phase 3 clinical trials.
News
|
|
4 min read
Cystic Fibrosis Foundation Drug Development Model Spawns More Than 30 Promising Therapies
Press Release
|
|
3 min read
Press Release
|
|
6 min read
Press Release
|
|
5 min read
Press Release
|
|
3 min read
News
|
|
3 min read